Investors

Medivir to present at the Pareto Securities Healthcare Conference

Medivir´s Partner Tango Therapeutics received FDA clearance to start the TNG348 phase 1/2 clinical study

Medivir presents data on additive activity of fostrox in combination with Lenvima or sorafenib in non-clinical tumor models at ILCA